摘要
目的:探讨特异性p38蛋白激酶(p38MAPK)抑制剂SB203580对哮喘小鼠气道炎症和Th1／Th2类细胞因子(IFN-γ／IL-4)变化的影响。方法:BALB／c小鼠30只随机分成3组:正常对照组、哮喘模型组和SB203580干预组。采用酶联免疫吸附法(ELISA)检测支气管肺泡灌洗液(BALF)中IL-4和IFN-γ含量,并观察BALF中炎症细胞和肺组织病理学改变。结果:与正常对照组比较,哮喘模型组小鼠BALF中炎症细胞计数和IL-4水平升高而IFN-γ水平降低(P<0.01);与哮喘模型组比较,SB203580干预组小鼠BALF中炎症细胞计数和IL-4水平明显降低,IFN-γ水平明显上升(P<0.01),肺组织病理学改变显著减轻。结论:SB203580能抑制哮喘小鼠的气道炎症反应,纠正IFN-γ／IL-4平衡的失调。
AIM: To investigate the effects of SB203580, a special inhibitor of p38 mitogen-activated protein kinase (p38 MAPK), on the airway inflammation and Th1/Th2 cytokines, IFN-γ/IL-4 in mice with asthmatic. METHODS: Thirty mice were randomly divided into 3 groups: normal control group, asthmatic group and SB203580 group. The concentrations of IFN-γ and IL-4 in bronchial alveolar lavage fluid (BALF) were measured by ELISA. The number of inflammatory cells in BALF and the changes of histropathology were observed. RESULTS: In asthmatic group, the number of inflammatory cells and the concentration of IL-4 in BALF were higherand the concentration of in BALF IFN-γwas lower than those in normal control group( P < 0.01) . In SB203580 group, the number of inflammatory cells and the concentration of IL-4 in BALF were lower and the concentration of in BALF IFN-γwas higher than those in asthmatic group (P < 0.01). Meanwhile, the histropathology damage was alleviated in SB203580 group. CONCLUSION: SB203580 can decrease the aggregation of airway inflammatory cells and correct the imbalance of IFN-γ/IL-4.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2004年第11期1256-1259,共4页
Chinese Journal of Clinical Pharmacology and Therapeutics
基金
本课题受湖北省教育厅科研基金资助(№2003B004)
关键词
P38蛋白激酶
哮喘
气道炎症
细胞因子
MAPK
p38 MAPK
bronchial
asthma
airway inflammation
cytokine
IFN-γ
Interleukin-4
